Faron Pharmaceuticals Ltd: Appointment of CFO

Faron Pharmaceuticals OyAnnouncement

Yesterday 07:00

Faron Pharmaceuticals Ltd | Company announcement | December 01, 2025 at
09:00:00 EET

Faron appoints new CFO to support next phase of growth

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company, announces the appointment of Mr.
Jurriaan Dekkers as the company’s Chief Financial Officer (CFO) as of 1
December 2025.

Mr. Dekkers brings more than 20 years of experience in biopharma and
healthcare companies. Most recently, he has been the CFO at ProQR
Therapeutics, a biotechnology company developing RNA therapies for severe
unmet medical needs. Prior to that, he served as CFO of AstraZeneca in the
Netherlands and CEO of Acerta Pharma (part of the AstraZeneca Group). He has
also held global and European finance roles at DaVita Medical Group, a
US-listed international healthcare provider, and Sandvik, amongst others. 

He currently serves as a Supervisory Board member and Audit Committee Member
at Stichting Kinderpostzegels in the Netherlands.

Mr. Dekkers holds a MSc. in Economics from the Erasmus University Rotterdam,
the Netherlands, and is a Certified Public Auditor (Register Accountant, RA)
graduate from the Erasmus University Rotterdam.

“We are very happy to welcome Jurriaan into Faron’s team in this exciting
growth phase of Faron. His experience and proven track record of fundraising
and strategic and commercial growth initiatives will support the advancement
of our lead asset bexmarilimab as it enters the registrational study”,
comments Dr. Juho Jalkanen, CEO of Faron.

The Company’s current CFO Yrjö Wichmann will be retiring having played a key
role in supporting the Company’s strategic transition and growth over a number
of years. Mr. Wichmann will remain with the Company for a transitional period
until end of 1Q2026 to ensure continuity.

Dr. Juho Jalkanen, CEO of Faron, said, “I would like to thank Yrjö for his
great contributions to Faron over the years. Yrjö has had a key role both in
the early stages of the Company as well as the more recent phases of growth
and transition. Yrjö is an essential part of Faron’s history and the spirit of
the Company. We will miss him, and wish him all the best in his retirement.”

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             | +358 50 553 9535 / +44 7 469 766 223 |
|                                     |         kare.laukkanen@irpartners.fi |
| Kare Laukkanen                      |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   |                     +1 847 791-8085  |
| (Media)                             |        alyssa.paldo@finnpartners.com |
| Alyssa Paldo                        |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        |                 +44 (0) 207 213 0880 |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    |                  +358 (0)40 555 4727 |
| (Certified Adviser on Nasdaq First  |                  +358 (0)50 553 8990 |
| North)                              |                                      |
| Juha Karttunen                      |                                      |
| Jukka Järvelä                       |                                      |
+-------------------------------------+--------------------------------------+

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune
system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on
macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on
macrophages, bexmarilimab alters the tumor microenvironment, reprogramming
macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1)
one, upregulating interferon production and priming the immune system to
attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The company’s lead asset, bexmarilimab, is a novel
macrophage-guiding immunotherapy being investigated in multiple oncology
settings. Further information is available at www.faron.com
(http://www.faron.com/)